Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Drug Profile

Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Alternative Names: ASP 7373; Avian influenza (bird flu) vaccine - Protein Sciences Corporation/UMN Pharma; H7-rHA; HA vaccine for H5N1 (UMN 0501) - Protein Sciences Corporation; HA vaccine for H9N2 (UMN 0901) - Protein Sciences Corporation; Influenza A (H1N1) vaccine - Protein Sciences Corporation/Vaxine; Influenza A virus H5N1 vaccine - UMN Pharma; Influenza A virus H7N9 vaccine - Protein Sciences Corporation; Panblok; PanBlok; Panblok H1/2009; Panblok-H7; Pandemic H5N1 influenza vaccine - Protein Sciences Corporation/UMN Pharma; Pandemic influenza virus (swine flu) vaccine - Vaxine; Recombinant H5 (rH5) pandemic influenza vaccine (Panblok) - Protein Sciences Corporation; Recombinant haemagglutinin (rHA) influenza vaccine; Recombinant influenza H5N1 vaccine (UMN-0501) - UMN Pharma; UMN 0901; UMN-0501

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Ildong Pharmaceutical; Protein Sciences Corporation; UMN Pharma; Vaxine
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza A virus H9N2 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
  • Preclinical Influenza A virus H9N2 subtype
  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Nov 2017 UMN 0901 is still in preclinical trials for Influenza-A virus H9N2 subtype (prevention) in China, Hong Kong, Japan, Singapore, South Korea and Taiwan
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in Australia (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A virus H9N2 subtype(Prevention) in China (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top